Published in Inflamm Bowel Dis on January 01, 2008
Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.15
Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion (2009) 0.87
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Endoscopic ultrasound to guide the combined medical and surgical management of pediatric perianal Crohn's disease. Inflamm Bowel Dis (2010) 0.82
Making therapeutic decisions in inflammatory bowel disease: the role of patients. Curr Opin Gastroenterol (2009) 0.79
Patient perspectives on the impact of Crohn's disease: results from group interviews. Patient Prefer Adherence (2012) 0.78
Assessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire. Clin Exp Gastroenterol (2011) 0.78
Personalizing evidence-based primary prevention with aspirin: individualized risks and patient preference. Circ Cardiovasc Qual Outcomes (2011) 0.77
Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis (2010) 0.77
Exploring the understanding of evidence-based concepts in people with type 2 diabetes. Int J Gen Med (2012) 0.76
Are Expectations Too High for Transitioning Adolescents With Inflammatory Bowel Disease? Examining Adult Medication Knowledge and Self-Management Skills. J Pediatr Gastroenterol Nutr (2016) 0.75
Patient Perspectives on Therapeutic Options for IBD. Gastroenterol Hepatol (N Y) (2007) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology (2012) 4.13
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Rice consumption and urinary arsenic concentrations in U.S. children. Environ Health Perspect (2012) 2.44
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
Effect of prior cardiac operations on survival after coronary artery bypass grafting. Ann Thorac Surg (2011) 2.02
Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med (2012) 1.92
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol (2008) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.58
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Perioperative increases in serum creatinine are predictive of increased 90-day mortality after coronary artery bypass graft surgery. Circulation (2006) 1.53
Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care (2011) 1.52
Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicenter U.S. series. Gastrointest Endosc (2011) 1.44
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc (2013) 1.38
Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25
Lubiprostone: a chloride channel activator. J Clin Gastroenterol (2007) 1.24
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis (2013) 1.12
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
Fecal transplantation: beyond the aesthetic. Gastroenterology (2013) 1.07
Public directory data sources do not accurately characterize the food environment in two predominantly rural states. J Am Diet Assoc (2011) 1.06
Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis (2006) 1.05
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis (2012) 1.00
Acute appendicitis following colonoscopy. J Clin Gastroenterol (2005) 1.00
Risk factors for colon ischemia. Am J Gastroenterol (2004) 1.00
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2006) 0.99
State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis (2005) 0.98
A longitudinal analysis of rural and urban veterans' health-related quality of life. J Rural Health (2010) 0.98
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut (2011) 0.97
A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol (2013) 0.96
The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut (2007) 0.96
Impact of workplace sociocultural attributes on participation in health assessments. J Occup Environ Med (2009) 0.93
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol (2003) 0.92
Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol (2007) 0.92
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother (2003) 0.92
The impact of waist circumference on function and physical activity in older adults: longitudinal observational data from the osteoarthritis initiative. Nutr J (2014) 0.91
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis (2011) 0.89
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis (2013) 0.86
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol (2008) 0.85
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis (2009) 0.85
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scand J Gastroenterol (2015) 0.84
Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis (2010) 0.83
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging (2008) 0.82
Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab (2003) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology (2015) 0.80
Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. Inflamm Bowel Dis (2014) 0.80
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2013) 0.80
Hemoconcentration and pancreatic necrosis: further defining the relationship. Pancreas (2006) 0.80
Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study. Inflamm Bowel Dis (2015) 0.80
Anatomic and functional outcomes of sacrocolpopexy with or without posterior colporrhaphy. Int Urogynecol J (2012) 0.79
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamm Bowel Dis (2015) 0.78
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis (2010) 0.78
Quality of care for cardiometabolic disease: associations with mental disorder and rurality. Med Care (2010) 0.78
Healthcare intensity is associated with lower ratings of healthcare quality by younger adults. J Ambul Care Manage (2009) 0.78
Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc (2015) 0.78
The United States Chiropractic Workforce: An alternative or complement to primary care? Chiropr Man Therap (2012) 0.78
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis (2017) 0.78
Babesiosis in a patient on infliximab for Crohn's disease. Inflamm Bowel Dis (2010) 0.77
Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians. Med Health R I (2012) 0.77
A predictive model of outcomes during cerebral aneurysm coiling. J Neurointerv Surg (2013) 0.77
Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 0.77
The usefulness and cost of a shorter duration of fasting in workplace screening for glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract (2009) 0.77
Body image dissatisfaction in patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.77
Does tight glucose control prevent myocardial injury and inflammation? J Extra Corpor Technol (2011) 0.76
Within you, without you: is gastroenterology ready to embrace the "exposome"? Gastroenterology (2012) 0.76
Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers. Inflamm Bowel Dis (2016) 0.75
Risk of traumatic injury associated with chiropractic spinal manipulation in Medicare Part B beneficiaries aged 66 to 99 years. Spine (Phila Pa 1976) (2015) 0.75